Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Phase 3CompletedNCT00691964

AbbVie (prior sponsor, Abbott)347 enrolled

Overview

Compare the efficacy of ABT-874 versus etanercept in subjects with moderate to severe plaque psoriasis

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Enrollment

347

Conditions

Plaque Psoriasis

Interventions

ABT-874BIOLOGICAL

SQ injection 200 mg Weeks 0 and 4; 100 mg Week 8

etanerceptBIOLOGICAL

SQ injection 50 mg BIW

placeboDRUG

SQ placebo injections for ABT-874 and etanercept

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosis of Psoriasis for 6 mo. * BSA 10%, PASI 12 or above, PGA 3 or above Exclusion Criteria: * Previous exposure to either etanercept or ABT-874

Locations (35)

Outcomes

Primary Outcomes

Proportion of subjects who achieve a PGA of 0 or 1 response relative to baseline at Week 12

Time frame: 12 Weeks

Proportion of subjects who achieve a PASI 75 response relative to baseline at Week 12

Time frame: 12 Weeks

Secondary Outcomes

Proportion of subjects who achieve a PASI 100 response relative to baseline at Week 12

Time frame: 12 Weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Site Reference ID/Investigator# 8478

Tucson, Arizona, United States

Site Reference ID/Investigator# 8462

Fresno, California, United States

Site Reference ID/Investigator# 8454

Los Angeles, California, United States

Site Reference ID/Investigator# 8476

Denver, Colorado, United States

Site Reference ID/Investigator# 9641

Miami, Florida, United States

Site Reference ID/Investigator# 8463

Alpharetta, Georgia, United States

Site Reference ID/Investigator# 8479

Arlington Heights, Illinois, United States

Site Reference ID/Investigator# 8527

Schaumburg, Illinois, United States

Site Reference ID/Investigator# 9001

Skokie, Illinois, United States

Site Reference ID/Investigator# 8466

West Dundee, Illinois, United States

...and 25 more locations